Company Overview of PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. develops biotherapeutics to treat metabolic and cardiopulmonary disorders. Its development candidates include PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment of acute and chronic heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and changed its name to PhaseBio Pharmaceuticals, Inc. in October, 2006. The company was founded in 2002 and is based in Malvern, Pennsylvania.
One Great Valley Parkway
Malvern, PA 19355
Founded in 2002
Key Executives for PhaseBio Pharmaceuticals, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2017.
PhaseBio Pharmaceuticals, Inc. Key Developments
PhaseBio Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 11:40 AM
Mar 21 17
PhaseBio Pharmaceuticals, Inc. Presents at 16th Annual Needham Healthcare Conference, Apr-05-2017 11:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jonathan P. Mow, Chief Executive Officer and Director.
PhaseBio Pharmaceuticals, Inc. Announces Dosing of First Patients in Two-Part Phase 2a Study of PB1046 in Cardiopulmonary Disorders
Aug 8 16
PhaseBio Pharmaceuticals, Inc. announced the dosing of the first patients in Part One of a Phase 2a clinical study of PB1046, a once-weekly vasoactive intestinal peptide (VIP) receptor agonist in development for the treatment of cardiopulmonary disorders. Part One will assess PB1046 in adult subjects with stable heart failure with reduced ejection fraction. Part Two, which PhaseBio expects to initiate later in 2016, will examine PB1046 in subjects with cardiac dysfunction secondary to Duchenne muscular dystrophy. Part One is a randomized, double-blind, placebo-controlled, multiple-dose study evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic response following four weeks of once-weekly subcutaneous injections of PB1046 in 28 adults with heart failure. Dose levels shown to be safe and well-tolerated in Part One will be selected for evaluation in Part Two of the study. PB1046 is based on vasoactive intestinal peptide (VIP), a naturally occurring neuropeptide that exerts its physiological effects through activation of the G-protein coupled receptors VPAC1 and VPAC2, which are widely distributed throughout the cardiovascular, pulmonary and immune systems. To date, the inherently poor in vivo stability and bioavailability of the native peptide have limited its therapeutic use. PB1046 is a genetic fusion of an analogue of VIP with PhaseBio’s elastin-like polypeptide biopolymer, which overcomes these limitations and demonstrates prolonged circulatory drug exposure and potent activity. PB1046 was designed to be relatively selective in binding to the VPAC2 receptor to reduce potential gastrointestinal side effects believed to be associated with excessive activation of the VPAC1 receptor. PB1046 has been shown to be highly effective in animal models of hypertension, pulmonary arterial hypertension and heart failure, with positive cardiac inotropic (contractility) and lusitropic (relaxation) effects without an increase in myocardial oxygen demand. Additional pre-clinical data demonstrated that chronic administration of PB1046 in a murine model of DMD (mdx mouse) significantly slowed the deterioration of cardiac function. In a Phase 1 single-ascending-dose study, PB1046 was well-tolerated and demonstrated a prolonged, dose-dependent effect on blood pressure when administered subcutaneously to patients with essential hypertension. This supported a second Phase 1 single-ascending-dose study in patients with essential hypertension, in which PB1046 was administered intravenously to support use in an acute setting. PB1046 has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cardiomyopathy associated with dystrophinopathies.
PhaseBio Pharmaceuticals, Inc. Appoints John S. Lee as Chief Medical Officer and John P. Sharp as Chief Financial Officer
Apr 7 16
PhaseBio Pharmaceuticals, Inc. announced the expansion of its leadership teams in Malvern, PA, and San Diego, CA, effective April 18, 2016. John S. Lee, M.D., Ph.D., has been appointed as Chief Medical Officer and will be based at PhaseBio’s corporate headquarters in Malvern. John P. Sharp, CPA, has been named as Chief Financial Officer and will be based in San Diego. Dr. Lee joins PhaseBio from Quintiles, where he served as Vice President & Global Head, Cardiovascular Center of Excellence. Mr. Sharp joins PhaseBio from HUYA Bioscience International, where he served as Chief Financial Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 17, 2017